JBC Focus on PI3-Kinase with Echelon

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cook, T.
Right arrow Articles by Urrutia, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cook, T.
Right arrow Articles by Urrutia, R.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 274, Issue 41, 29500-29504, October 8, 1999


Three Conserved Transcriptional Repressor Domains Are a Defining Feature of the TIEG Subfamily of Sp1-like Zinc Finger Proteins*

Tiffany CookDagger §, Brian Gebelein§parallel , Mohammad BelalDagger , Kristin MesaDagger , and Raul UrrutiaDagger parallel **Dagger Dagger

From the Dagger  Gastroenterology Research Unit, parallel  Department of Molecular Neurosciences, and ** Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota 55901

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
CONCLUSION
REFERENCES

Sp1-like transcription factors are characterized by three highly homologous C-terminal zinc finger motifs that bind GC-rich sequences. These proteins behave as either activators or repressors and have begun to be classified into different subfamilies based upon the presence of conserved motifs outside the zinc finger domain. This classification predicts that different Sp1-like subfamilies share certain functional properties. TIEG1 and TIEG2 constitute a new subfamily of transforming growth factor-beta -inducible Sp1-like proteins whose zinc finger motifs also bind GC-rich sequences. However, regions outside of the DNA-binding domain that differ in structure from other Sp1-like family members remain poorly characterized. Here, we have used extensive mutagenesis and GAL4-based transcriptional assays to identify three repression domains within TIEG1 and TIEG2 that we call R1, R2, and R3. R1 is 10 amino acids, R2 is 12 amino acids, and R3 is approximately 80 amino acids long. None of these domains share homology with previously described transcriptional regulatory motifs, but they share strong sequence homology and are functionally conserved between TIEG1 and TIEG2. Together, these data demonstrate that TIEG proteins are capable of repressing transcription, define domains critical for this function, and further support the idea that different subfamilies of Sp1-like proteins have evolved to mediate distinct transcriptional functions.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
CONCLUSION
REFERENCES

Sp1-like transcription factors have recently elicited significant attention because of their widespread participation in the regulation of mammalian cell homeostasis (1). Members of this family of proteins currently include Sp1-4, BTEB1, BTEB2/IKLF, TIEG1/MGIF, TIEG2, BKLF, EKLF, GKLF/EZF, LKLF, CPBP/Bcd, and AP2-rep, all of which are characterized by three highly conserved C2H2 zinc finger DNA-binding domains at their C termini (2-21). Sp1-like transcription factors share over 75% similarity within these three zinc finger domains. Because of this high similarity, it is not surprising that many of these proteins bind to similar GC-rich sequences within promoters (reviewed in Ref. 1). These GC-rich sequences contribute to the regulation of a large number of genes necessary for various cellular functions, including cell proliferation, differentiation, and apoptosis (22). Thus, because of their participation in these functions, many Sp1-like proteins also function as key regulators of morphogenesis (1).

While the DNA-binding domain of the Sp1-like transcription factor family is highly conserved, the N-terminal regions of the proteins are more divergent. Interestingly, it is through this domain that many of these transcription factors regulate transcription (7, 14, 17-19, 23-30). The founding member of this family, Sp1, for example, is a potent transcriptional activator that utilizes glutamine-rich sequences located within its N terminus to interact with proteins from the basal transcriptional apparatus to regulate gene expression (23). In contrast, BKLF behaves as a transcriptional repressor through a distinct domain within its N terminus (30). Interestingly, other members of the Sp1-like family, such as GKLF, can behave as either a transcriptional activator or a transcriptional repressor through two independent regulatory domains (19). However, for several of the Sp1-like family members, the domains responsible for transcriptional regulation have not yet been defined.

TIEG1 is a widely expressed zinc finger transcription factor originally identified as the product of a TGFbeta -inducible gene from osteoblastic cell populations (10). Studies from our laboratory have revealed that TIEG1 is a novel member of the Sp1-like family of transcription factors that inhibits the growth of epithelial cell populations (15). Subsequent studies from other laboratories have demonstrated that the inhibitory effect of TIEG1 on cell growth is also observed in mesenchymal cells (31). Moreover, recent reports have shown that TIEG1 is a target of glial cell-derived neurotrophic factor-mediated signaling in neuronal cells (16). Thus, TIEG1 appears to be part of the molecular machinery that regulates the growth of cells from various lineages. As the result of a search for novel Sp1-like transcription factors, we have recently identified TIEG2, a protein structurally related to TIEG1 (17). These two proteins are 91% similar within the C-terminal DNA-binding domain and 44% similar throughout their N termini. Like TIEG1, TIEG2 is inducible by TGFbeta signaling and inhibits epithelial cell growth. Thus, based upon their sequence similarity, TGFbeta inducibility, and effect on epithelial cell proliferation, we have proposed that TIEG1 and TIEG2 form a distinct subgroup of Sp1-like transcription factors (17).

With the goal of better understanding molecular mechanisms underlying the function of TIEG1 and TIEG2, our laboratory has focused on defining the structural domains used by these proteins to regulate gene expression in mammalian cells. We and others have recently demonstrated that the zinc finger motifs of both TIEG1 and TIEG2 bind to GC-rich Sp1-like cis-regulatory sequences (16, 17). The functional consequence of this interaction is the repression of promoters containing GC-rich sequences, and at least for TIEG2, the N-terminal region of this protein is sufficient to mediate repression (16, 17). In the current study, we show that the N terminus of TIEG1 also mediates repression, revealing that this region has a conserved transcriptional function in both TIEG proteins. More importantly, using deletion and site-directed mutagenesis together with transcriptional regulatory assays, we have defined three independent transcriptional repression domains conserved within TIEG proteins that we call R1, R2, and R3. R1 and R2 are 10- and 12-amino acids long, respectively, while R3 is a longer proline-rich sequence of approximately 80 aa. Interestingly, in contrast to several other members of the Sp1-like family, no transcriptional activation domain was found to be present in these transcription factors (7, 8, 14, 18, 19, 23-26, 28, 29). Together, these data strongly support the biochemical similarity between TIEG1 and TIEG2 and indicate that they primarily function to silence gene expression. Furthermore, these results expand our understanding of the repertoire of functional domains present in Sp1-like transcription factors for the regulation of gene expression in mammalian cells. The importance of these results for extending the classification of Sp1-like proteins is discussed.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
CONCLUSION
REFERENCES

Generation of GAL4 Effector Plasmids-- TIEG2-GAL4 constructs were generated by amplifying various regions of TIEG2 by polymerase chain reaction and cloning these in frame with the pSG424 GAL4 DBD1 effector plasmid (kindly provided by Dr. N. J. Zeleznik-Le, University of Chicago, IL). TIEG1 constructs were generated in the same manner. All TIEG2 constructs were numbered by amino acid using the second in-frame methionine of the originally published sequence (the codon that best fits the Kozak consensus translational start site) as amino acid residue 1 (17). Site-directed proline mutagenesis of the R1 and R2 domains was performed by annealing overlapping mutant primers that span the region of interest. Mutagenesis of the R3 domain was performed using standard overlapping polymerase chain reaction mutagenesis. All constructs were verified by sequencing.

GAL4-based Transcriptional Regulatory Assays-- GAL4-based transcriptional regulatory assays were performed as described previously (17). Briefly, 3 × 105 CHO cells were plated in 60-mm tissue culture dishes and transfected 48 h later with 3 µg of GAL4 effector plasmid DNA, 1 µg of GAL45tkCAT reporter (generously provided by Dr. N. J. Zeleznik-Le), and 1 µg of pHook-LacZ (InVitrogen, Carlsbad, CA) using LipofectAMINETM (Life Technologies, Inc.). As a control for basal transcriptional activity, the reporter construct was co-transfected with an effector plasmid carrying the GAL4 DNA-binding domain alone. Co-transfection with a beta -galactosidase expression plasmid, pHook-LacZ (Promega), was performed to control for transfection efficiency. Relative CAT activity was assayed using an enzyme-linked immunosorbent assay method from Roche Molecular Biochemicals, and beta -galactosidase activity was measured using the beta -galactosidase enzyme assay system (Promega). In all experiments, CAT activity was determined using the same amount of protein (50 µg), and the values were normalized to beta -galactosidase activity. Studies were performed in triplicate in at least three independent experiments with similar results.

Gel Shift Assays-- To ascertain expression levels of each GAL4 chimeric transcription factor used in these studies, electromobility shift assays were performed essentially as described previously (17, 32, 33). Briefly, concomitant with the transfection for the GAL4-based transcriptional regulatory assay, an additional 60-mm dish of CHO cells was co-transfected with 3 µg (or as indicated) of each effector plasmid and 2 µg of filler DNA (pcDNA3.1+; InVitrogen). 48 h post-transfection, cells were washed twice with ice-cold PBS, harvested by scraping, and pelleted at 3000 × g for 5 min. Cells were then lysed in 35 µl of whole cell extract buffer (20 mM Tris, pH 7.5, 20% glycerol, 0.5 M KCl, 1 mM phenylmethylsulfonyl fluoride, 5 µg/ml aprotinin, 1 mM dithiothreitol), frozen at -80 °C, and thawed at 4 °C. Cellular debris and unlysed cells were pelleted at 10,000 × g for 10 min at 4 °C, and lysates were transferred to fresh tubes. Protein concentrations were assayed using the BCA method (Pierce). 10 µg of whole cell extracts was incubated 10 min at room temperature in a buffer containing 4% glycerol, 1 mM MgCl2, 0.5 mM EDTA, 0.5 mM dithiothreitol, 50 mM NaCl, 10 mM Tris-HCl, pH 7.5, and 50 µg/ml poly(dI-dC)·poly(dI-dC) (Promega, Madison, WI). A double-stranded GAL4 DNA-binding site, 5'-GGAGTACTGTCCTCCGAG-3' was end-labeled with [gamma -32P]ATP with T4 polynucleotide kinase according to the manufacturer's suggestions (Promega, Madison, WI). 0.35 pmol of end-labeled GAL4 probe was then added to each reaction for an additional 20 min, and the reactions were loaded immediately onto a 4% nondenaturing polyacrylamide gel. Samples were run for 3 h at 120 V at room temperature, vacuum-dried, and exposed to X-Omat film (Eastman Kodak Co.) at room temperature.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
CONCLUSION
REFERENCES

TIEG1 and TIEG2 Act as Potent Transcriptional Repressor Proteins-- Several studies have recently revealed the existence of a novel subfamily of Sp1-like transcription factors, TIEG1 and TIEG2, that inhibit growth of epithelial cell populations (15, 17). These proteins share 91% similarity within their C-terminal zinc finger DNA-binding domain and 44% similarity within a proline-rich N terminus. Previous biochemical studies have demonstrated that both of these proteins bind to GC-rich sequences and repress transcription of promoters containing these sites (16, 17). In addition, the N-terminal region of TIEG2, when tethered to DNA through a heterologous DBD, behaves as a potent transcriptional repression domain (17) (Fig. 1). To test whether the homologous region of TIEG1 has a similar function, in the current study, we fused the N and C terminus of TIEG1 to the GAL4 DBD and tested its ability to regulate a promoter carrying five GAL4 DNA-binding sites upstream of a CAT reporter gene. Indeed, Fig. 1b demonstrates that the N-terminal regions of both TIEG1 and TIEG2 are able to repress transcription by over 95%, whereas the C-terminal regions display no transcriptional regulatory activity. Together, these results demonstrate that the N-terminal regions of the TIEG proteins display functionally conserved transcriptional repression activity.


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 1.   TIEG1 and TIEG2 contain a potent transcriptional repression domain within their N termini. a, chimeric cDNAs were generated by cloning the N or C terminus of TIEG1 and TIEG2 in frame with the DNA-binding domain of the yeast transcription factor GAL4 (GAL4 DBD). b, these constructs were tested for the ability to regulate transcription of the CAT reporter gene driven by a promoter carrying five GAL4 DNA-binding sites. Assays were performed in CHO cells. Bars, S.D. Note that the N-terminal region of both TIEG1 and TIEG2 strongly represses transcription compared with the DBD alone, while the C-terminal regions have no transcriptional regulatory effect.

Deletion Mutagenesis of the N Terminus of TIEG2 Reveals the Presence of Three Transcriptional Repressor Domains-- To identify domains utilized by TIEG proteins to regulate transcription, we generated a number of deletion and site-directed mutants as GAL4-TIEG chimeric constructs. The expression and the ability of each of these proteins to bind GAL4 DNA-binding sites was confirmed using gel shift assays as described under "Experimental Procedures" (data not shown). The results shown in Fig. 2 delineate three distinct domains within TIEG2, R1 (aa 24-41), R2 (aa 151-162), and R3 (aa 273-351), that repress reporter activity by at least 75%. R1 and R2 are small peptides (17 and 12 aa, respectively), whereas R3 is a larger domain composed of approximately 80 aa (residues 273-351). Regions outside of the R1, R2, and R3 domains display no transcriptional regulatory activity (Fig. 2b). Furthermore, smaller deletion constructs within R1 (27-34), R2 (158-160), and R3 (273-303 and 304-351) display a loss of repression activity, indicating that the domains defined using this analysis represent the minimal functional units necessary for transcriptional repression.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 2.   Mapping of the transcriptional regulatory domains within TIEG2. Various portions of the N-terminal region of TIEG2 were tested in the GAL4 transcriptional regulatory assay described in Fig. 1. a, lines indicate the position of the construct tested compared with the N terminus of TIEG2; corresponding amino acids are listed to the left; and the average percentage of CAT expression compared with expression by the GAL4 DBD alone (100%) is listed to the right. b, histogram representing the relative CAT expression for constructs spanning the regions between or the regions encoding the R1, R2, and R3 domains. These domains were defined as the minimal sequences tested that provide transcriptional regulatory activity greater than 3-fold over control. Bars, S.D.

Identification of Residues Critical for R1, R2, and R3 to Repress Transcription Using Site-directed Mutagenesis-- To more precisely define the residues responsible for the transcriptional regulatory activity of R1, R2, and R3, we used extensive site-directed mutagenesis. Computer-based modeling studies of the R1 domain using SOPMA software (34) (available on the Internet) predicts that this sequence is capable of forming an alpha -helical structure. Therefore, we generated sequential mutations along the R1 domain of TIEG2 using the helix-breaking proline residue as a mutagen (Fig. 3a). We then tested each of these mutants for their ability to maintain transcriptional repression. As shown in Fig. 3, mutations within the central core of the R1 domain, corresponding to amino acid residues 30-39 (AVEALVCMSS), resulted in a complete loss of transcriptional regulatory activity, while mutations outside of this core did not abolish repression. Additional results demonstrate that this decapeptide is also sufficient to repress transcription. Therefore, these results define a 10-aa core sequence that is required for the R1 domain to function.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 3.   Mapping of the residues involved in R1-mediated repression. a, consecutive mutations within the R1 domain of TIEG2 were generated by replacing each amino acid residue with a proline. These mutant R1 domains were then tested in a GAL4 assay (b). Mutations 5-14, corresponding to the amino acid sequence AVEALCMSS, were unable to repress reporter activity more than 2-fold, while mutations outside this region could still support transcriptional repression. Furthermore, a construct encoding the residues mapped using proline mutagenesis, AVEALVCMSS, is sufficient to repress transcription. Bars, S.D.

Using a similar approach, we characterized the R2 and R3 domains of TIEG2. Mutation of nine of the 12 residues that compose R2 did not significantly influence repression (Fig. 4). In contrast, mutations in three consecutive residues, Val, Ile, and Arg (aa 158-160), resulted in a complete loss of repression activity by R2. However, these three residues alone (GAL4-VIR) were not sufficient to repress reporter activity. This result suggests that while the VIR peptide is essential for R2-mediated repression, the remainder of the R2 domain also contributes to its function.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 4.   Mapping of the residues involved in R2-mediated repression. Scanning proline mutations were generated to span the entire R2 domain of TIEG2 (a). These mutant GAL4 DBD chimeric effector plasmids were then tested for their ability to regulate transcription (b). Note that only mutations in residues VIR (constructs 8-10) lose the ability to repress transcription. However, a GAL4 DBD-VIR (VIR) construct is not sufficient to repress transcription.

The R3 domain of TIEG2 contains two interesting features. First, R3 is relatively proline-rich (20%), a feature that is commonly found in activation and repression domains (35, 36). Second, the R3 domain contains a core sequence of approximately 20 aa (aa 311-328) that is highly conserved (67% similar) between TIEG1 and TIEG2 (see Fig. 6). Because of the high proline content of R3, we used serine mutants to characterize this domain (Fig. 5a). Three of these mutants involved changing clusters of proline residues near the beginning (aa 288-290), middle (aa 306-310), or end (aa 332-336) of this domain; an additional mutant changed seven of the central conserved residues (aa 317-323). As shown in Fig. 5b, all of the proline-to-serine mutants were still able to repress transcription, indicating that these proline residues are not essential for the ability of R3 to repress transcription. In contrast, mutation of the conserved core abolishes the ability of R3 to repress transcription. Interestingly, one of the constructs used to define the R3 domain (304-351, Fig. 2) contains this conserved sequence but is only able to repress transcription by ~42% versus 77% for the full R3 domain. This result suggests that the central core sequence is necessary but not sufficient for full R3-mediated repression activity.


View larger version (12K):
[in this window]
[in a new window]
 
Fig. 5.   Mapping of the residues involved in R3-mediated repression. a, four serine-based mutants were generated in the R3 domain of TIEG2. Mutants 1, 2, and 4 mutate prolines to serines, while mutant 3 changes a core of residues present within a conserved region between TIEG1 and TIEG2 (shaded). These mutant GAL4 DBD chimeric effector plasmids were tested for their ability to regulate transcription (b). Note that mutations in the proline residues do not affect the ability of the R3 domain to repress transcription (1, 2, 4), while a mutation of the conserved region alleviates transcriptional repression (3).

R1, R2, and R3 Are Conserved Repression Domains within the TIEG Family of Transcription Factors-- An important feature of the repression domains described above is that they share strong sequence homology between both TIEG proteins (65, 75, and 29% similar for R1, R2, and R3, respectively) (Fig. 6a). In addition, the central core of R3, a region that is required for repression, is 67% similar between TIEG1 and TIEG2. To determine whether these three domains are functionally conserved between the TIEG proteins, we tested the ability of the corresponding regions of TIEG1 to regulate transcription (Fig. 6b). Indeed, the R1, R2, and R3 regions of TIEG1 also repress transcription. Furthermore, the residues that are critical for TIEG2 repression share remarkable similarity (>= 80%) between both TIEG proteins (Figs. 3-6). Interestingly, the data presented in Figs. 2 and 6 also suggested that the R1, R2, and R3 domains exhibit different levels of repressor activity. To assess their differential strengths, we compared dose-response curves for R1, R2, and R3 from TIEG2. From these experiments, we find that all three domains display repression activity in a dose-dependent manner. However, the R1, R2, and R3 domains exhibit different relative strengths: 92, 84, and 51% repression, respectively, at the highest dose tested. For this comparison, gel shift analysis of each GAL4-TIEG2 chimeric protein was performed to determine equal DNA binding activity (Fig. 7b). Together, these results reveal that the three distinct transcriptional repressor domains are not only structurally conserved but are also functionally conserved within the TIEG subfamily of Sp1-like proteins.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 6.   R1, R2, and R3 are conserved in TIEG1 and TIEG2. a, sequence comparisons of the R1, R2, and R3 domains of TIEG2 (from Fig. 2) compared with TIEG1 show a remarkable conservation between these regions. The R1 domain is 65% similar, the R2 domain is 75% similar, and the R3 domain is 29% similar. Dark gray indicates identical residues, and light gray indicates similar residues. Proline residues in the R3 domain are boxed, and a core of ~20 aa in the R3 domain that is 67% similar between TIEG2 and TIEG1 is marked with asterisks. No other homology was detected with other proteins using existing data bases. b, histogram representing relative CAT expression from GAL4-TIEG1 constructs carrying the putative R1, R2, and R3 domains. Bars, S.D. Note that in addition to being homologous, each of these domains is functionally conserved between TIEG1 and TIEG2.


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 7.   Dose-dependent repression activity of R1, R2, and R3. a, GAL4-based transcriptional regulatory assay using increasing amounts of effector plasmids (DBD and R1: 0.25, 0.5, 1, and 2 µg; R2 and R3: 0.0375, 0.075, 0.15, and 0.3 µg). Effector and reporter plasmids were transfected in CHO cells and analyzed for relative CAT expression as described under "Experimental Procedures." Bars, S.D. Note that in all cases, a dose-dependent repression is observed, and under all conditions, the R1 domain most effectively represses transcription. b, CHO cells were transfected with 2 µg of the GAL4-DBD, 2 µg of R1, 0.3 µg of R2, or 0.3 µg of R3 effector plasmid. pcDNA3.1+ plasmid was added to each transfection to reach a total of 5 µg, and transfections were performed concomitantly with the experiment in a as described under "Experimental Procedures." 10 µg of whole cell lysates from each sample were then used in a gel shift assay using the GAL4 DNA-binding site as a probe. The asterisk indicates a degradation product. This experiment was performed three times with identical results.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
CONCLUSION
REFERENCES

Continuing with our studies on the functional characterization of novel members of the Sp1-like family of proteins, in this report we demonstrate that the presence of three conserved transcriptional repression domains is a defining biochemical property of TIEG proteins. Sp1-like proteins are characterized by the presence of three highly related C2H2 zinc finger DNA-binding motifs (1). Currently, at least 14 different members of the Sp1-like family of transcription factors have been shown to regulate promoters containing GC-rich sequences (1). Interestingly, these sequences are present in the promoters of more than 1000 different gene products (2, 22, 37, 38). Therefore, a detailed analysis of the transcriptional regulatory properties of Sp1-like proteins will be critical for beginning to understand the complexity of gene expression in mammalian cells.

Several laboratories are attempting to define distinct subgroups within the growing family of Sp1-like proteins based upon the presence of conserved regions located outside of the zinc finger motif. We and others have recently reported that this classification can help to predict biochemical and functional properties of novel proteins that are being added to this family of transcription factors (reviewed in Ref. 1). In addition, these studies are providing useful information for understanding whether different members of the Sp1-like family of proteins display distinct or redundant functions. The Sp1-like subgroups that have been identified thus far include the SP (Sp1, Sp2, Sp3, and Sp4), BTEB (BTEB1 and BTEB2), KLF (EKLF, GKLF, and LKLF), CPBP (CPBP, Zf9, and UKLF), and TIEG (TIEG1 and TIEG2) proteins. The SP proteins contain glutamine-rich N-terminal transcriptional activation domains, the BTEB proteins activate transcription through a hydrophobic-rich domain, and the CPBP proteins encode an acidic activation domain (14, 18, 26, 28, 39). The KLF proteins are defined by the presence of two different types of conserved sequences that act as a nuclear localization signal and a putative proline-rich transcriptional regulatory domain, respectively (8, 19, 24, 40). As demonstrated in this study, the TIEG proteins are defined by the presence of three conserved sequences that act as transcriptional repressors. Thus, together this information suggests that different subfamilies of Sp1-like proteins have evolved to mediate distinct transcriptional functions.

Understanding the structure and function of distinct transcriptional regulatory motifs within transcription factor proteins constitutes an active field of research that has been helpful for understanding the control of gene expression. For instance, several activation domains have been recently identified on the basis of their amino acid compositions, including glutamine-, proline-, serine/threonine-, and acidic residue-rich domains (35, 38). Other activation domains, however, have recently been defined that do not fall into these categories, suggesting that a diverse array of domains can activate transcription. Emerging evidence indicates that many activation domains interact with specific co-activator proteins to regulate the basal transcriptional machinery or chromatin structure to increase transcription initiation. For example, the glutamine-rich regions of Sp1 activate transcription by binding to TAFII130 to recruit the RNA polymerase II-associated preinitiation complex to target promoters, while the proline-rich activation domain of EKLF specifically recruits E-RC1, a SWI-SNF chromatin remodeling complex, to allow transcriptional activation to occur (41-43). Therefore, different activation domains can initiate transcription through interactions with distinct co-activator proteins.

Although far less understood than transcriptional activation, repression is also crucial for the regulation of gene expression and morphogenesis. Over the past few years, several distinct transcriptional repression domains have been identified in eukaryotic transcription factors (36, 44). Like activation domains, these domains can be loosely classified into families based on amino acid composition. Some repression domains, for example, are charged, hydrophobic, alanine-, or proline-rich, whereas others are unique in amino acid composition. In addition, repression domains can range in size from as little as four amino acids to hundreds of amino acids long. The short peptide sequence WRP(W/Y) found in the Hairy and Runt families of transcriptional repressors, for example, is sufficient to repress transcription through interaction with members of the Groucho family of transcriptional co-repressors (45). In contrast, other repressor proteins, such as the thyroid hormone receptor, require the cooperative use of three large, less well defined, hydrophilic and hydrophobic regions in order to achieve full repressive activity (46). Similar to the WRP(W/Y) motif, the R1, R2, and core of the R3 domain of TIEG1 and TIEG2 are short amino acid sequences necessary for repression and are well conserved among family members. These results suggest a conserved mechanism for regulating transcription for TIEG proteins. It is therefore likely that the conserved repression domains of TIEG1 and TIEG2 are used to contact either one or more co-repressor molecules. Noteworthy, however, is that all three of the repression domains identified in this study represent novel sequences, sharing no specific homology with other regulatory domains. Because of the novelty of these sequences, it is difficult to speculate as to the identity of these co-repressor proteins. Therefore, identification of potential R1, R2, and R3 interacting proteins and the detailed characterization of these interactions will further increase our understanding of the mechanisms underlying TIEG-mediated transcriptional repression in mammalian cells.

    CONCLUSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
CONCLUSION
REFERENCES

Three novel transcriptional repressor domains are a defining feature of the TIEG subfamily of Sp1-like proteins. The presence of these domains suggest that, in contrast to other Sp1-like proteins, the TIEG subfamily has evolved to silence gene expression in mammalian cells. These results, together with previous studies from other laboratories, are being used to generate a structural and functional classification of the growing family of Sp1-like zinc finger proteins. This classification will be useful for predicting common as well as distinct biochemical and functional properties of members of this family.

    ACKNOWLEDGEMENTS

We thank Karen Hedin and Vijay Shaw for critically reviewing the manuscript.

    FOOTNOTES

* This work was supported by the Mayo Cancer Center and National Institutes of Health (NIH) Grant DK52913 (to R. U.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ These authors contributed equally to this work.

Supported by NIH Training Grant DK07198.

Dagger Dagger To whom correspondence should be addressed: GI Research Unit, Saint Mary's Hospital, Mayo Clinic, Rochester, MN 55905. Tel.: 507-284-7500; Fax: 507-255-6318; E-mail: urrutia.raul@mayo.edu.

    ABBREVIATIONS

The abbreviations used are: DBD, DNA-binding domain; CAT, chloramphenicol acetyltransferase; CHO, Chinese hamster ovary; aa, amino acid(s).

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
CONCLUSION
REFERENCES

1. Cook, T., Gebelein, B., and Urrutia, R. (1999) Ann. N. Y. Acad. Sci. 880, 94-102[CrossRef][Medline] [Order article via Infotrieve]
2. Kadonaga, J. T., Carner, K. R., Masiarz, F. R., and Tjian, R. (1987) Cell 51, 1079-1090[CrossRef][Medline] [Order article via Infotrieve]
3. Hagen, G., Muller, S., Beato, M., and Suske, G. (1992) Nucleic Acids Res. 20, 5519-5525[Abstract/Free Full Text]
4. Imataka, H., Sogawa, K., Yasumoto, K., Kikuchi, Y., Sasano, K., Kobayashi, A., Hayami, M., and Fujii-Kuriyama, Y. (1992) EMBO J. 11, 3663-3671[Medline] [Order article via Infotrieve]
5. Kingsley, C., and Winoto, A. (1992) Mol. Cell. Biol. 12, 4251-4261[Abstract/Free Full Text]
6. Miller, I. J., and Bieker, J. J. (1993) Mol. Cell. Biol. 13, 2776-2786[Abstract/Free Full Text]
7. Sogawa, K., Imataka, H., Yamasaki, Y., Kusume, H., Abe, H., and Fujii-Kuriyama, Y. (1993) Nucleic Acids Res. 21, 1527-1532[Abstract/Free Full Text]
8. Anderson, K. P., Kern, C. B., Crable, S. C., and Lingrel, J. B. (1995) Mol. Cell. Biol. 15, 5957-5965[Abstract]
9. Blok, L. J., Grossmann, M. E., Perry, J. E., and Tindall, D. J. (1995) Mol. Endocrinol. 9, 1610-1620[Abstract]
10. Subramaniam, M., Harris, S. A., Oursler, M. J., Rasmussen, K., Riggs, B. L., and Spelsberg, T. C. (1995) Nucleic Acids Res. 23, 4907-4912[Abstract/Free Full Text]
11. Crossley, M., Whitelaw, E., Perkins, A., Williams, G., Fujiwara, Y., and Orkin, S. H. (1996) Mol. Cell. Biol. 16, 1695-1705[Abstract]
12. El Rouby, S., and Newcomb, E. W. (1996) Oncogene 13, 2623-2630[Medline] [Order article via Infotrieve]
13. Shields, J. M., Christy, R. J., and Yang, V. W. (1996) J. Biol. Chem. 271, 20009-20017[Abstract/Free Full Text]
14. Koritschoner, N. P., Bocco, J. L., Panzetta-Dutari, G. M., Dumur, C. I., Flury, A., and Patrito, L. C. (1997) J. Biol. Chem. 272, 9573-9580[Abstract/Free Full Text]
15. Tachibana, I., Imoto, M., Adjei, P., Gores, G. J., Subramaniam, M., Spelsberg, T. C., and R., U. (1997) J. Clin. Invest. 99, 2365-2374[Medline] [Order article via Infotrieve]
16. Yajima, S., Lammers, C. H., Lee, S. H., Hara, Y., Mizuno, K., and Mouradian, M. M. (1997) J. Neurosci. 17, 8657-8666[Abstract/Free Full Text]
17. Cook, T., Gebelein, B., Mesa, K., Mladek, A., and Urrutia, R. (1998) J. Biol. Chem. 273, 25929-25936[Abstract/Free Full Text]
18. Matsumoto, N., Laub, F., Aldabe, R., Zhang, W., Ramirez, F., Yoshida, T., and Terada, M. (1998) J. Biol. Chem. 273, 28229-28237[Abstract/Free Full Text]
19. Yet, S. F., McA'Nulty, M. M., Folta, S. C., Yen, H. W., Yoshizumi, M., Hsieh, C. M., Layne, M. D., Chin, M. T., Wang, H., Perrella, M. A., Jain, M. K., and Lee, M. E. (1998) J. Biol. Chem. 273, 1026-1031[Abstract/Free Full Text]
20. Imhof, A., Schuierer, M., Werner, O., Moser, M., Roth, C., Bauer, R., and Buettner, R. (1999) Mol. Cell. Biol. 19, 194-204[Abstract/Free Full Text]
21. Conkright, M. D., Wani, M. A., Anderson, K. P., and Lingrel, J. B. (1999) Nucleic Acids Res. 27, 1263-1270[Abstract/Free Full Text]
22. Liu, C., Calogero, A., Ragona, G., Adamson, E., and Mercola, D. (1996) Crit. Rev. Oncogenesis 7, 101-125[Medline] [Order article via Infotrieve]
23. Courey, A. J., and Tjian, R. (1988) Cell 55, 887-898[CrossRef][Medline] [Order article via Infotrieve]
24. Bieker, J. J., and Southwood, C. M. (1995) Mol. Cell. Biol. 15, 852-860[Abstract]
25. Hagen, G., Dennig, J., Preiß, A., Beato, M., and Suske, G. (1995) J. Biol. Chem. 270, 24989-24994[Abstract/Free Full Text]
26. Kobayashi, A., Sogawa, K., Imataka, H., and Fujii-Kuriyama, Y. (1995) J. Biochem. (Tokyo) 117, 91-95[Abstract/Free Full Text]
27. Dennig, J., Beato, M., and Suske, G. (1996) EMBO J. 15, 5659-5667[Medline] [Order article via Infotrieve]
28. Kojima, S., Kobayashi, A., Gotoh, O., Ohkuma, Y., Fujii-Kuriyama, Y., and Sogawa, K. (1997) J. Biochem. (Tokyo) 121, 389-396[Abstract/Free Full Text]
29. Majello, B., De Luca, P., and Lania, L. (1997) J. Biol. Chem. 272, 4021-4026[Abstract/Free Full Text]
30. Turner, J., and Crossley, M. (1998) EMBO J. 17, 5129-5140[CrossRef][Medline] [Order article via Infotrieve]
31. Tau, K. R., Hefferan, T. E., Waters, K. M., Robinson, J. A., Subramaniam, M., Riggs, B. L., and Spelsberg, T. C. (1998) Endocrinology 139, 1346-1353[Abstract/Free Full Text]
32. Alevizopoulos, A., and Mermod, N. (1996) J. Biol. Chem. 271, 29672-29681[Abstract/Free Full Text]
33. Martinez, E., Dusserre, Y., Wahli, W., and Mermod, N. (1991) Mol. Cell. Biol. 11, 2937-2945[Abstract/Free Full Text]
34. Geourjon, C., and Deleage, G. (1995) Comp. Appl. Biosci. 11, 681-684[Abstract/Free Full Text]
35. Triezenberg, S. J. (1995) Curr. Opin. Genet. Dev. 5, 190-196[CrossRef][Medline] [Order article via Infotrieve]
36. Hanna-Rose, W., and Hansen, U. (1996) Trends Genet. 12, 229-234[CrossRef][Medline] [Order article via Infotrieve]
37. Dynan, W. S., and Tjian, R. (1985) Nature 316, 774-778[CrossRef][Medline] [Order article via Infotrieve]
38. Mitchell, P. J., and Tjian, R. (1989) Science 245, 371-378[Abstract/Free Full Text]
39. Lania, L., Majello, B., and De Luca, P. (1997) Intl. J. Biochem. Cell Biol. 29, 1313-1323[CrossRef][Medline] [Order article via Infotrieve]
40. Shields, J. M., and Yang, V. W. (1997) J. Biol. Chem. 272, 18504-18507[Abstract/Free Full Text]
41. Gill, G., Pascal, E., Tseng, Z. H., and Tjian, R. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 192-196[Abstract/Free Full Text]
42. Tanese, N., Saluja, D., Vassallo, M. F., Chen, J. L., and Admon, A. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 13611-13616[Abstract/Free Full Text]
43. Armstrong, J. A., Bieker, J. J., and Emerson, B. M. (1998) Cell 95, 93-104[CrossRef][Medline] [Order article via Infotrieve]
44. Gray, S., and Levine, M. (1996) Curr. Opin. Cell Biol. 8, 358-364[CrossRef][Medline] [Order article via Infotrieve]
45. Fisher, A. L., and Caudy, M. (1998) Genes Dev. 12, 1931-1940[Free Full Text]
46. Busch, K., Martin, B., Baniahmad, A., Renkawitz, R., and Muller, M. (1997) Mol. Endocrinol. 11, 379-389[Abstract/Free Full Text]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
R. Alvarez-Rodriguez, M. Barzi, J. Berenguer, and S. Pons
Bone Morphogenetic Protein 2 Opposes Shh-mediated Proliferation in Cerebellar Granule Cells through a TIEG-1-based Regulation of Nmyc
J. Biol. Chem., December 21, 2007; 282(51): 37170 - 37180.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. Fujimura, T. Vacik, O. Machon, C. Vlcek, S. Scalabrin, M. Speth, D. Diep, S. Krauss, and Z. Kozmik
Wnt-mediated Down-regulation of Sp1 Target Genes by a Transcriptional Repressor Sp5
J. Biol. Chem., January 12, 2007; 282(2): 1225 - 1237.
[Abstract] [Full Text] [PDF]


Home page
J Biomol ScreenHome page
P.-Q. Liu, S. Tan, M. C. Mendel, R. J. Murrills, B. M. Bhat, B. Schlag, R. Samuel, J. J. Matteo, R. de la Rosa, K. Howes, et al.
Isogenic Human Cell Lines for Drug Discovery: Regulation of Target Gene Expression by Engineered Zinc-Finger Protein Transcription Factors
J Biomol Screen, June 1, 2005; 10(4): 304 - 313.
[Abstract] [PDF]


Home page
Mol. Cell. Biol.Home page
M. Subramaniam, G. Gorny, S. A. Johnsen, D. G. Monroe, G. L. Evans, D. G. Fraser, D. J. Rickard, K. Rasmussen, J. M. A. van Deursen, R. T. Turner, et al.
TIEG1 Null Mouse-Derived Osteoblasts Are Defective in Mineralization and in Support of Osteoclast Differentiation In Vitro
Mol. Cell. Biol., February 1, 2005; 25(3): 1191 - 1199.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Cao, M. E. Fernandez-Zapico, D. Jin, V. Puri, T. A. Cook, L. O. Lerman, X.-Y. Zhu, R. Urrutia, and V. Shah
KLF11-mediated Repression Antagonizes Sp1/Sterol-responsive Element-binding protein-induced Transcriptional Activation of Caveolin-1 in Response to Cholesterol Signaling
J. Biol. Chem., January 21, 2005; 280(3): 1901 - 1910.
[Abstract] [Full Text] [PDF]


Home page
Crit. Rev. Oral Biol. Med.Home page
B. Ganss and A. Jheon
ZINC FINGER TRANSCRIPTION FACTORS IN SKELETAL DEVELOPMENT
Crit. Rev. Oral. Biol. Med., September 1, 2004; 15(5): 282 - 297.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. D. Noti, A. K. Johnson, and J. D. Dillon
The Zinc Finger Transcription Factor Transforming Growth Factor {beta}-Inducible Early Gene-1 Confers Myeloid-specific Activation of the Leukocyte Integrin CD11d Promoter
J. Biol. Chem., June 25, 2004; 279(26): 26948 - 26958.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
X.-M. Ou, K. Chen, and J. C. Shih
Dual Functions of Transcription Factors, Transforming Growth Factor-{beta}-inducible Early Gene (TIEG)2 and Sp3, Are Mediated by CACCC Element and Sp1 Sites of Human Monoamine Oxidase (MAO) B Gene
J. Biol. Chem., May 14, 2004; 279(20): 21021 - 21028.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
D. C. Tomlinson, J. C. Grindley, and A. A. Thomson
Regulation of Fgf10 Gene Expression in the Prostate: Identification of Transforming Growth Factor-{beta}1 and Promoter Elements
Endocrinology, April 1, 2004; 145(4): 1988 - 1995.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
R. A. Abbud, R. Kelleher, and S. Melmed
Cell-Specific Pituitary Gene Expression Profiles after Treatment with Leukemia Inhibitory Factor Reveal Novel Modulators for Proopiomelanocortin Expression
Endocrinology, February 1, 2004; 145(2): 867 - 880.
[Abstract] [Full Text] [PDF]


Home page
Plant Physiol.Home page
M. A. Rabbani, K. Maruyama, H. Abe, M. A. Khan, K. Katsura, Y. Ito, K. Yoshiwara, M. Seki, K. Shinozaki, and K. Yamaguchi-Shinozaki
Monitoring Expression Profiles of Rice Genes under Cold, Drought, and High-Salinity Stresses and Abscisic Acid Application Using cDNA Microarray and RNA Gel-Blot Analyses
Plant Physiology, December 1, 2003; 133(4): 1755 - 1767.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
S. A. Johnsen, M. Subramaniam, D. G. Monroe, R. Janknecht, and T. C. Spelsberg
Modulation of Transforming Growth Factor beta (TGFbeta )/Smad Transcriptional Responses through Targeted Degradation of TGFbeta -inducible Early Gene-1 by Human Seven in Absentia Homologue
J. Biol. Chem., August 16, 2002; 277(34): 30754 - 30759.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
J.-S. Zhang, M. C. Moncrieffe, J. Kaczynski, V. Ellenrieder, F. G. Prendergast, and R. Urrutia
A Conserved {alpha}-Helical Motif Mediates the Interaction of Sp1-Like Transcriptional Repressors with the Corepressor mSin3A
Mol. Cell. Biol., August 1, 2001; 21(15): 5041 - 5049.
[Abstract] [Full Text] [PDF]

<